Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,90
KB-0,76
PKN8282,6-2,59
Msft0,73
Nokia5,145,18-1,64
IBM-0,63
DCX61,861,82-0,95
PFE-0,55
19.6.2018 1:38:59
Indexy online
AD Index online
select
AD Index online
 

  • 18.6.2018 22:00:00
Concert Pharm (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
19,43 -1,37 -0,27 85 530
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.6.2018
Popis společnosti
Obecné informace
Název společnostiConcert Pharmaceuticals Inc
TickerCNCE
Kmenové akcie:Ordinary Shares
RICCNCE.O
ISINUS2060221056
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 64
Akcie v oběhu k 1.5.2018 23 395 816
Počet akcionářů k 31.12.2017 17
MěnaUSD
Kontaktní informace
Ulice99 Hayden Ave Ste 500
MěstoLEXINGTON
PSČ02421-7966
ZeměUnited States
Kontatní osobaJustine Koenigsberg
Funkce kontaktní osobyVice President - Corporate Communications
Telefon17 818 600 045
Fax13026365454
Kontatní telefon17 816 745 284

Business Summary: Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
Financial Summary: BRIEF: For the three months ended 31 March 2018, Concert Pharmaceuticals Inc revenues increased from $20K to $10.5M. Net loss decreased 67% to $4.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment Income increase from $137K to $640K (income), General & Admin exp decrease of 11% to $3.9M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Co-FounderRichard Aldrich62
President, Chief Executive Officer, Co-Founder, DirectorRoger Tung57
Principal Financial Officer, Principal Accounting OfficerRyan Lynch-15.6.2017
Chief Financial OfficerMarc Becker454.1.20184.1.2018
Chief Operating OfficerNancy Stuart55
Senior Vice President and General CounselIan Silverman63
Senior Vice President, chief development officerJames Cassella,-
Vice President - Regulatory AffairsChristine Boisclair-6.9.20166.9.2016
Vice President - Commercial and Product StrategyScott Weintraub-6.9.20166.9.2016